H7T1 Stoklara Genel Bakış HUTCHMED (China) Limited, iştirakleriyle birlikte, Hong Kong'da ve uluslararası alanda kanser ve immünolojik hastalıklar için hedefe yönelik terapötikler ve immünoterapiler keşfetmekte, geliştirmekte ve ticarileştirmektedir. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
HUTCHMED (China) Limited Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti HUTCHMED (China) Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı UK£13.50 52 Haftanın En Yüksek Seviyesi UK£19.90 52 Haftanın En Düşük Seviyesi UK£11.10 Beta 0.74 1 Aylık Değişim -17.18% 3 Aylık Değişim -12.34% 1 Yıllık Değişim -11.18% 3 Yıllık Değişim -55.59% 5 Yıllık Değişim -38.64% Halka arzdan bu yana değişim -41.36%
Son Haberler & Güncellemeler
Hutchmed (China) Limited Announces Breakthrough Therapy Designation in China for Orpathys®? and Tagrisso®? Combination in Certain Lung Cancer Patients After Disease Progression on Egfr Inhibitor Therapy Dec 12
HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024 Nov 20
HUTCHMED (China) Limited Announces Positive High-Level Results from the SAVANNAH Phase II Trial Oct 16
Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer Sep 09
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China Aug 30
HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024 Jul 31 Daha fazla güncelleme görün
Hutchmed (China) Limited Announces Breakthrough Therapy Designation in China for Orpathys®? and Tagrisso®? Combination in Certain Lung Cancer Patients After Disease Progression on Egfr Inhibitor Therapy Dec 12
HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024 Nov 20
HUTCHMED (China) Limited Announces Positive High-Level Results from the SAVANNAH Phase II Trial Oct 16
Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer Sep 09
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China Aug 30
HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024 Jul 31
HUTCHMED (China) Limited to Report First Half, 2024 Results on Jul 31, 2024 Jun 26
Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology Jun 19
HUTCHMED (China) Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China Jun 08
HUTCHMED (China) Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine Jun 05
HUTCHMED (China) Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology May 25 HUTCHMED (China) Limited Announces Executive Changes
HUTCHMED (China) Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China May 15
HUTCHMED (China) Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui May 14
HUTCHMED (China) Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024 May 09
HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024 Apr 09
HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024 Apr 05
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status Apr 03
HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC Mar 28
Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China Mar 22
HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024 Feb 29
Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session Feb 07
HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024 Feb 01
HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer Jan 30
HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status Jan 11
HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China Dec 13
Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors Dec 01
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer Nov 09
HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan Oct 01
HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer Sep 13
Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China Sep 12
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer Aug 29
HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China Aug 21
HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study Jul 22
HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee Jul 14
Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China Jul 12
HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023 Jun 27 HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet Jun 17
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency Jun 16
HUTCHMED (China) Limited and Takeda Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review May 31
HUTCHMED (China) Limited Announces New and Updated Clinical Data Related to HUTCHMED May 26
HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee May 11
HUTCHMED (China) Limited to Report Fiscal Year 2022 Results on Feb 28, 2023 Jan 31
HUTCHMED (China) Limited Announces Agreement with NHSA for Inclusion of ORPATHYS in the National Reimbursement Drug List in China Jan 19
Hutchmed Completes Patient Enrollment of Eslim-01, A Phase Iii Trial of Sovleplenib in Primary Immune Thrombocytopenia in China Jan 04
HUTCHMED Initiates Rolling Submission of Nda to U.S. Fda for Fruquintinib for the Treatment of Refractory Colorectal Cancer Dec 20
HUTCHMED (China) Limited Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China Nov 14 Hutchmed (China) Limited Initiates Phase 2/3 Trial of Fruquintinib Oct 28
HUTCHMED (China) Limited Initiates Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China Oct 11
HUTCHMED (China) Limited Announces Summary Results of the 691-Patient, Multi-Regional Clinical Trial Sep 08
Inmagene Biopharmaceuticals and HUTCHMED (China) Limited Announce First Participant in Global Phase I Trial of IMG-004 Aug 10 HUTCHMED (China) Limited Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
HUTCHMED (China) Limited Announces Fruquintinib Global Phase III FRESCO-2 Study in Metastatic Colorectal Cancer Aug 08
HUTCHMED (China) Limited Initiates A Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China Aug 01
HUTCHMED (China) Limited Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China Jul 16
HUTCHMED (China) Limited Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting Jul 13
Inmagene Biopharmaceuticals and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007 Jul 07
HUTCHMED (China) Limited to Report First Half, 2022 Results on Aug 01, 2022 Jun 08
HUTCHMED Announces TAZVERIK(R) Approved to be Used in Hainan Pilot Zone in China Jun 02
HUTCHMED (China) Limited Announces Board Changes May 18 HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2022
HUTCHMED (China) Limited Receives Approval to Commercialize Elunate in Macau Mar 03
HUTCHMED (China) Limited to Report Fiscal Year 2021 Final Results on Mar 03, 2022 Feb 08
HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China Feb 05
HUTCHMED (China) Limited Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China Jan 20
HUTCHMED (China) Limited Update Analysis of Ongoing International Phase I/Ib Trial of Fruquintinib Jan 19
HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia Jan 13
HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China Jan 10
Hutchmed (China) Limited Completes Planned Enrollment of FRESCO-2, A Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer Dec 07
HUTCHMED (China) Limited and AstraZeneca PLC Initiate Sachi Phase III Trial of Orpathys® and Tagrisso® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy Nov 24
HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in China Sep 21
HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma Sep 14
HUTCHMED (China) Limited and AstraZeneca PLC Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China Sep 09
Hutchmed Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer Aug 26
European Medicines Agency Accepts Marketing Authorization Application for Hutchmed (China) Limited's Surufatinib Jul 16
HUTCHMED (China) Limited Initiates Phase I Trials of novel ERK inhibitor HMPL 295 in Patients with Advanced Solid Tumors in China Jul 06
U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors Jul 02
HUTCHMED (China) Limited has completed a Follow-on Equity Offering in the amount of HKD 4.1704 billion. Jun 25
HUTCHMED (China) Limited Announces Savolitinib Approval in China for Patients with Lung Cancer with MET Exon 14 Skipping Alterations Jun 24
Hutchmed (China) Limited Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors Jun 22 Hissedar Getirileri H7T1 DE Pharmaceuticals DE Pazar 7D -4.9% -1.7% -1.6% 1Y -11.2% -15.8% 6.8%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: H7T1 geçen yıl % -15.8 oranında getiri sağlayan German Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: H7T1 geçen yıl % 6.8 oranında getiri sağlayan German Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is H7T1's price volatile compared to industry and market? H7T1 volatility H7T1 Average Weekly Movement 6.9% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: H7T1 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: H7T1 'nin haftalık oynaklığı ( 7% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.
Şirket Hakkında HUTCHMED (China) Limited, iştirakleriyle birlikte, Hong Kong'da ve uluslararası alanda kanser ve immünolojik hastalıklar için hedefe yönelik terapötikler ve immünoterapiler keşfetmekte, geliştirmekte ve ticarileştirmektedir. Şirket, küçük hücreli dışı akciğer kanseri (NSCLC), papiller renal hücreli karsinom (RCC) ve mide kanseri (GC) tedavisi için Savolitinib ve kolorektal kanser (CRC), meme kanseri, mide kanseri, mikrosatellit stabil-CRC endometriyal kanser (EMC), NSCLC, RCC, gastrointestinal, servikal ve solid tümörler için bir inhibitör olan Fruquintinib'i geliştirmektedir. Ayrıca, pankreatik nöroendokrin tümör (NET), pankreatik olmayan NET, nöroendokrin karsinom, SCLC, safra yolu kanseri ve solid tümörlerin tedavisinde kullanılan Surufatinib ve hematolojik kanserleri ve bazı kronik bağışıklık hastalıklarını tedavi eden Sovleplenib'i geliştirmektedir.
Daha fazla göster HUTCHMED (China) Limited Temel Bilgiler Özeti HUTCHMED (China)'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? H7T1 temel i̇stati̇sti̇kler Piyasa değeri €2.49b Kazançlar(TTM ) -€40.37m Gelir(TTM ) €587.53m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) H7T1 gelir tablosu (TTM ) Gelir US$610.81m Gelir Maliyeti US$658.26m Brüt Kâr -US$47.45m Diğer Giderler -US$5.48m Kazançlar -US$41.97m
Son Raporlanan Kazançlar
Jun 30, 2024
Hisse başına kazanç (EPS) -0.049 Brüt Marj -7.77% Net Kâr Marjı -6.87% Borç/Özkaynak Oranı 10.9%
H7T1 uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/25 15:56 Gün Sonu Hisse Fiyatı 2024/12/23 00:00 Kazançlar 2024/06/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları HUTCHMED (China) Limited 46 Bu analistlerden 22, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Jiangqiao Tong BOCI Research Ltd. Linda Lu BOCI Research Ltd. Alec Stranahan BofA Global Research
Göster 43 daha fazla analist 
